Little vascular plasters

Trigen Holdings AG sees its PR-15 as a bandage that moves through the bloodstream patching up collagen exposed in damaged vascular walls. The company thinks the platelet adhesion inhibitor may have less severe bleeding side effects than marketed antiplatelet therapies and have the potential to replace treatment with GPIIb/IIIa inhibitors.

Last week, Trigen (Munich, Germany) exclusively licensed IP from Millennium Pharmaceuticals Inc. (MLNM, Cambridge, Mass.) covering the platelet surface receptor glycoprotein VI (GPVI) as a therapeutic target. The move frees Trigen to pursue GPVI-related programs that it acquired from cardiovascular company ProCorde GmbH in 2005(see B4 & BioCentury, April 18, 2005). ...